Corporate Information – ASCELIA

All All press releases Regulatory press releases Financial reports

Regulatory

2021-05-05 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2021

Regulatory

2021-04-15 | Ascelia Pharma AB publishes prospectus regarding admission to trading of newly issued shares on Nasdaq Stockholm

Regulatory

2021-04-13 | Bulletin from the extraordinary general meeting in Ascelia Pharma AB

Regulatory

2021-04-09 | Issue and repurchase of series C shares for share saving program

Regulatory

2021-03-31 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB

Regulatory

2021-03-17 | Notice of extraordinary general meeting in Ascelia Pharma

2021-03-02 | Ascelia Pharma opens US office in preparation for Mangoral launch

2021-01-12 | Ascelia Pharma presents clinical development plan for Oncoral as a novel chemotherapy

Regulatory

2020-12-15 | Ascelia Pharma gets US patent for second generation Mangoral

Regulatory

2020-12-02 | New study shows Mangoral’s lesion visualization as effective as gadolinium contrast agent

2020-11-03 | EMA confirms Mangoral eligible for the centralized regulatory procedure in the EU

Regulatory

2020-10-21 | Upgraded estimate of addressable market for Mangoral to $500-600 million annually

2020-09-30 | Invitation to Ascelia Pharma’s virtual Capital Markets Day

2020-09-18 | First commercial scale manufacturing of Mangoral

2020-06-09 | Presentation of Ascelia Pharma at ABGSC Life Science Summit Day and Redeye Orphan Drug Day

2020-05-26 | Vator Securities: Ascelia Pharma: A delay. Fundamentals for Mangoral remain unchanged.

Regulatory

2020-05-20 | Updated SPARKLE timelines due to Covid-19 impact

Regulatory

2020-05-06 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 May 2020

Regulatory

2020-05-06 | First participant enrolled in the clinical hepatic impairment study with Mangoral

2020-04-16 | Patent for Oncoral approved in Japan